Overview

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to explore the safety and biological activity of NGR-hTNF. The safety will be established by clinical and laboratory assessment. The biological activity will be evaluated by DCE-MRI with contrast media.
Phase:
Phase 1
Details
Lead Sponsor:
AGC Biologics S.p.A.
MolMed S.p.A.